Eledon Pharmaceuticals Inc. (ELDN)
$3.20
$-0.12
(-3.61%)
As on 28-Aug-2026 16:29EDT
Market cap
$260 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
8.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.8
-
Debt to Equity
0
-
Book Value
$0.9
-
EPS
$-1
-
Face value
--
-
Shares outstanding
81,261,152
10 Years Aggregate
CFO
$-251.64 Mln
EBITDA
$-230.16 Mln
Net Profit
$-336.55 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eledon Pharmaceuticals (ELDN)
| 111.9 | -10.4 | -17.9 | 24.0 | 25.7 | -16.8 | -33.2 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Eledon Pharmaceuticals (ELDN)
| -63.3 | 127.3 | -21.1 | -48.3 | -71.4 | 47.5 | -63.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eledon Pharmaceuticals (ELDN)
|
3.2 | 260.0 | 0.0 | -98.6 | -- | -128.7 | -- | 8.2 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Eledon Pharmaceuticals (ELDN)
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat... amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Read more
-
CEO & Non Independent Director
Dr. David-Alexandre C. Gros M.D., Ph.D.
-
CEO & Non Independent Director
Dr. David-Alexandre C. Gros M.D., Ph.D.
-
Headquarters
Irvine, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Eledon Pharmaceuticals (ELDN)
What is the current share price of Eledon Pharmaceuticals Inc (ELDN) Today?
The share price of Eledon Pharmaceuticals Inc (ELDN) is $3.20 (NASDAQ) as of 28-Aug-2026 16:29 EDT. Eledon Pharmaceuticals Inc (ELDN) has given a return of 25.73% in the last 3 years.
What is the current PB & PE ratio of Eledon Pharmaceuticals Inc (ELDN)?
Since, TTM earnings of Eledon Pharmaceuticals Inc (ELDN) is negative, P/E ratio is not available.
The P/B ratio of Eledon Pharmaceuticals Inc (ELDN) is 8.17 times as on 28-Aug-2026, a 53 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.50 |
1.40 |
2024 |
-6.81 |
2.09 |
2023 |
-1.08 |
0.52 |
2022 |
-0.36 |
0.37 |
2021 |
-1.83 |
0.38 |
What is the 52 Week High and Low of Eledon Pharmaceuticals Inc (ELDN)?
The 52-week high and low of Eledon Pharmaceuticals Inc (ELDN) are Rs 4.60 and Rs 1.35 as of 30-Aug-2026.
What is the market cap of Eledon Pharmaceuticals Inc (ELDN)?
Eledon Pharmaceuticals Inc (ELDN) has a market capitalisation of $ 260 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Eledon Pharmaceuticals Inc (ELDN)?
Before investing in Eledon Pharmaceuticals Inc (ELDN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.